Advertisement

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome

Kerry J. Savage, Brian Skinnider, Mubarak Al-Mansour, Laurie H. Sehn, Randy D. Gascoyne and Joseph M. Connors

Article Figures & Data

Figures

  • Figure 1

    Outcome of limited stage NLPHL. (A) Era-to-era comparison of TTP of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0074). (B) Era-to-era comparison of PFS of limited-stage NLPHL treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .0024). (C) Era-to-era comparison of OS limited-stage NLPHL patients treated in the RT alone era (n = 32) or ABVD chemotherapy era (n = 56; P = .074).

Tables

  • Table 1

    A comparison of clinical features of NLPHL patients with limited-stage disease treated in the radiation alone or ABVD treatment era

    Clinical featureRadiation alone treatment era (n = 32), n (%)ABVD treatment era (n = 56), n (%)P
    Age > 40 y12 (37.5)22 (39).87
    Male sex24 (75)42 (75)1.0
    Stage 211 (34)23 (41).54
    B symptoms01 (2).45
    Mass size > 5 cm*5 (28)19 (34).63
    • * Mass size missing 15 patients.

  • Table 2